SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Garner William J

(Last)

(First)

(Middle)

C/O INMED PHARMACEUTICALS INC.

SUITE 310 - 815 HASTINGS STREET

(Street)

VANCOUVER

V6C 1B4

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
11/12/2020

3. Issuer Name and Ticker or Trading Symbol
InMed Pharmaceuticals Inc. [ INM ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Shares	3,788	I	Held by spouse

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Director Stock Option (Right to Buy)	06/10/2016	06/10/2021	Common Shares	24,242	$3.29⁽¹⁾	D
Director Stock Option (Right to Buy)	01/14/2019	01/14/2024	Common Shares	1,061	$12.65⁽²⁾	D
Director Stock Option (Right to Buy)	01/12/2020⁽⁴⁾	01/11/2025	Common Shares	1,061	$6.33⁽³⁾	D

Explanation of Responses:

1. Converted from Canadian exercise price of C$4.29 using an exchange rate of C$1.3039 = US$1.00.

2. Converted from Canadian exercise price of $16.50 using an exchange rate of C$1.3039 = US$1.00.

3. Converted from the Canadian exercise price of C$8.25 using an exchange rate of C$1.3039 = US$1.00.

4. The options were granted on January 12, 2020, and will fully vest on the earlier of January 12, 2021, or immediately prior to the Issuer's next annual general meeting.

Remarks:

Exhibit 24.1 Power of Attorney

	/s/ William J. Garner	11/12/2020
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.